In clinical studies, when taking desloratadine at a recommended dose of 5 mg per day, according to indications, including allergic rhinitis and chronic idiopathic urticaria, adverse reactions were reported in 3% of patients, which exceeded the same value in the placebo group.
Undesirable reactions noted more often than others and exceeding the occurrence rate in the placebo group: increased fatigue (1.2%), dryness of the oral mucosa (0.8%), headache (0.6%).
When using desloratadine in adults and adolescents at the recommended dose of 5 mg per day, the incidence of drowsiness is not higher than with placebo.
Childhood
In clinical studies involving 578 adolescents from 12 to 17 years, the most common reported headache. It occurred in 5.9% of patients receiving desloratadine and in 6.9% of patients taking placebo.
The incidence of undesired reactions found during clinical study of desloratadine, which exceeded the frequency of occurrence in the placebo group, as well as other undesirable reactions reported during the post-detection period, are listed below.
The incidence of adverse events was classified as follows: very often (≥1 / 10), often (≥1 / 100, <1/10), infrequently (≥1 / 1000, <1/100), rarely (≥1 / 10,000 , <1/1000), very rarely (<1/10000, including individual cases), the frequency is unknown (can not be estimated from the available data).
Disorders of the psyche: very rarely - hallucinations.
From the nervous system: often - headache; very rarely - dizziness, drowsiness, insomnia, psychomotor hyperactivity, convulsions.
From the heart: very rarely - tachycardia, palpitation; frequency unknown - interval elongation QT.
From the gastrointestinal tract: often - dryness of the oral mucosa; very rarely - abdominal pain, nausea, vomiting, indigestion, diarrhea.
From the liver and bile ducts: very rarely - increased activity of liver enzymes, increased concentrations of bilirubin, hepatitis; frequency is unknown - jaundice.
From the side of the rut and subcutaneous tissues: frequency unknown - photosensitivity.
From the osteomuscular system and connective tissue: very rarely - myalgia.
General disorders and disorders at the site of administration: often - increased fatigue; very rarely - hypersensitivity reactions (such as anaphylaxis, angioedema, dyspnea, pruritus, rash, urticaria); frequency unknown - asthenia.
Postpayment period
Childhood: frequency unknown - interval elongation QT, arrhythmia, bradycardia.
If any of the side effects listed in the instruction are aggravated, or you notice any other side effects not listed in the instructions, inform the doctor about it.